Literature DB >> 12517830

Regional distribution of antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 in men and women in Ontario, Canada.

Michelle Howard1, John W Sellors, Dan Jang, Noah J Robinson, Margaret Fearon, Janusz Kaczorowski, Max Chernesky.   

Abstract

This study estimated the regional and age- and gender-specific seroprevalences of herpes simplex virus type 1 (HSV-1) and HSV-2 in Ontario, Canada. Stored serum specimens from subjects aged 15 to 44 years, including men (n = 979), women not under prenatal care (n = 638), and women under prenatal care (n = 701) submitted for routine viral serology were randomly selected according to regional population size from public health laboratories. HSV-1 and HSV-2 testing was done with the MRL enzyme immunoassay (EIA) (Focus Technologies), and HSV-2 was also tested by the Gull/Meridian EIA. Specimens discordant for HSV-2 antibodies between the two EIAs were resolved by a recombinant immunoblot assay (Focus Technologies). The overall age- and gender-standardized seroprevalences of HSV-1 and HSV-2 were 51.1% (95% confidence interval [CI], 50.1 to 52.1) and 9.1% (95% CI, 8.6 to 9.7), respectively. The seroprevalence of HSV-1 antibodies increased from 26.9 to 54.7% in men between 15 to 16 and 40 to 44 years of age, from 32.0 to 88.7% in women not under prenatal care, and from 55.2 to 69.2% in women under prenatal care. The seroprevalence of HSV-2 increased from 3.8 to 21.3% in men between 15 to 16 and 40 to 44 years of age, from 0 to 18.9% in women not under prenatal care, and from 3.4 to 23.1% in women under prenatal care. HSV-2 results were discordant for 3.3% (76 of 2,318) of specimens. Both types of HSV antibodies appeared to be acquired earlier among women under prenatal care than among men and women not under prenatal care. Antibodies were more prevalent among people in northern Ontario (72.9% of subjects [range, 68.4 to 77.4%] for HSV-1 and 13.7% of subjects [95% CI, 10.2 to 17.2%] for HSV-2) than elsewhere.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12517830      PMCID: PMC149555          DOI: 10.1128/JCM.41.1.84-89.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Herpes simplex virus type 2 in the United States, 1976 to 1994.

Authors:  D T Fleming; G M McQuillan; R E Johnson; A J Nahmias; S O Aral; F K Lee; M E St Louis
Journal:  N Engl J Med       Date:  1997-10-16       Impact factor: 91.245

2.  Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis.

Authors:  Anna Wald; Katherine Link
Journal:  J Infect Dis       Date:  2001-12-14       Impact factor: 5.226

3.  Genital herpes and public health: addressing a global problem.

Authors:  L Corey; H H Handsfield
Journal:  JAMA       Date:  2000-02-09       Impact factor: 56.272

4.  A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group.

Authors:  A G Langenberg; L Corey; R L Ashley; W P Leong; S E Straus
Journal:  N Engl J Med       Date:  1999-11-04       Impact factor: 91.245

Review 5.  High prevalence of herpes simplex virus type 1 in female anogenital herpes simplex in Newcastle upon Tyne 1983-92.

Authors:  S C Tayal; R S Pattman
Journal:  Int J STD AIDS       Date:  1994 Sep-Oct       Impact factor: 1.359

Review 6.  Herpes simplex virus-2 infection. An emerging disease?

Authors:  M Schomogyi; A Wald; L Corey
Journal:  Infect Dis Clin North Am       Date:  1998-03       Impact factor: 5.982

7.  The acquisition of herpes simplex virus during pregnancy.

Authors:  Z A Brown; S Selke; J Zeh; J Kopelman; A Maslow; R L Ashley; D H Watts; S Berry; M Herd; L Corey
Journal:  N Engl J Med       Date:  1997-08-21       Impact factor: 91.245

8.  Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention.

Authors:  W E Lafferty; L Downey; C Celum; A Wald
Journal:  J Infect Dis       Date:  2000-04-13       Impact factor: 5.226

9.  Decline of herpes simplex virus type 2 and Chlamydia trachomatis infections from 1970 to 1993 indicated by a similar change in antibody pattern.

Authors:  K Persson; A Månsson; E Jönsson; E Nordenfelt
Journal:  Scand J Infect Dis       Date:  1995

10.  Underdiagnosis of genital herpes by current clinical and viral-isolation procedures.

Authors:  L A Koutsky; C E Stevens; K K Holmes; R L Ashley; N B Kiviat; C W Critchlow; L Corey
Journal:  N Engl J Med       Date:  1992-06-04       Impact factor: 91.245

View more
  22 in total

1.  Safety of antiviral medication for the treatment of herpes during pregnancy.

Authors:  So-Hee Kang; Angela Chua-Gocheco; Pina Bozzo; Adrienne Einarson
Journal:  Can Fam Physician       Date:  2011-04       Impact factor: 3.275

2.  Prevention and management of neonatal herpes simplex virus infections.

Authors:  Upton D Allen; Joan L Robinson
Journal:  Paediatr Child Health       Date:  2014-04       Impact factor: 2.253

3.  Genital herpes in Canada: Deciphering the hidden epidemic.

Authors:  Mubeen Aslam; Rhonda Y Kropp; Gayatri Jayaraman; Katherine Dinner; Thomas Wong; Marc Steben
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

4.  Degeneration and regeneration of corneal nerves in response to HSV-1 infection.

Authors:  Ana J Chucair-Elliott; Min Zheng; Daniel J J Carr
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-01-13       Impact factor: 4.799

Review 5.  A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2.

Authors:  K J Looker; G P Garnett
Journal:  Sex Transm Infect       Date:  2005-04       Impact factor: 3.519

6.  Using centralized laboratory data to monitor trends in herpes simplex virus type 1 and 2 infection in British Columbia and the changing etiology of genital herpes.

Authors:  Mark Gilbert; Xuan Li; Martin Petric; Mel Krajden; Judith L Isaac-Renton; Gina Ogilvie; Michael L Rekart
Journal:  Can J Public Health       Date:  2011 May-Jun

7.  Tumor necrosis factor alpha and interleukin-6 facilitate corneal lymphangiogenesis in response to herpes simplex virus 1 infection.

Authors:  Katie M Bryant-Hudson; Hem R Gurung; Min Zheng; Daniel J J Carr
Journal:  J Virol       Date:  2014-10-08       Impact factor: 5.103

8.  The diagnosis of genital herpes - beyond culture: An evidence-based guide for the utilization of polymerase chain reaction and herpes simplex virus type-specific serology.

Authors:  S Ratnam; A Severini; G Zahariadis; M Petric; B Romanowski
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-07       Impact factor: 2.471

9.  HSV-1 targets lymphatic vessels in the eye and draining lymph node of mice leading to edema in the absence of a functional type I interferon response.

Authors:  Katie M Bryant-Hudson; Ana J Chucair-Elliott; Christopher D Conrady; Alex Cohen; Min Zheng; Daniel J J Carr
Journal:  Am J Pathol       Date:  2013-08-02       Impact factor: 4.307

10.  Suppressive valacyclovir therapy to reduce genital herpes transmission: good public health policy?

Authors:  Paul E Bonnar
Journal:  Mcgill J Med       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.